51 related articles for article (PubMed ID: 12454510)
1. Potentiation of
Purohit NK; Shah RG; Adant S; Hoepfner M; Shah GM; Beauregard JM
Oncotarget; 2018 May; 9(37):24693-24706. PubMed ID: 29872498
[TBL] [Abstract][Full Text] [Related]
2. Effects of the interferon-inducer ABPP on colon cancer in rats; importance of tumor load and tumor site.
Eggermont AM; Marquet RL; de Bruin RW; Jeekel J
Cancer Immunol Immunother; 1986; 22(3):217-20. PubMed ID: 2942251
[TBL] [Abstract][Full Text] [Related]
3. The Neuropeptide System and Colorectal Cancer Liver Metastases: Mechanisms and Management.
Kasprzak A; Adamek A
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32429087
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.
Wang CH; Tang CW; Liu CL; Tang LP
World J Gastroenterol; 2003 Sep; 9(9):1904-8. PubMed ID: 12970873
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: a new treatment for liver metastases.
Mearadji A; Breeman W; Hofland L; van Koetsveld P; Marquet R; Jeekel J; Krenning E; van Eijck C
Ann Surg; 2002 Dec; 236(6):722-8; discussion 728-9. PubMed ID: 12454510
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
Breeman WA; Mearadji A; Capello A; Bernard BF; van Eijck CH; Krenning EP; de Jong M
Int J Cancer; 2003 Apr; 104(3):376-9. PubMed ID: 12569562
[TBL] [Abstract][Full Text] [Related]
8. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
10. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model.
Lewis JS; Wang M; Laforest R; Wang F; Erion JL; Bugaj JE; Srinivasan A; Anderson CJ
Int J Cancer; 2001 Dec; 94(6):873-7. PubMed ID: 11745491
[TBL] [Abstract][Full Text] [Related]
14. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
